| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:40 UTC |
|---|
| HMDB ID | HMDB0014570 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Famciclovir |
|---|
| Description | Famciclovir, also known as famvir or BRL-42810, belongs to the class of organic compounds known as purines and purine derivatives. These are aromatic heterocyclic compounds containing a purine moiety, which is formed a pyrimidine-ring ring fused to an imidazole ring. Famciclovir is a drug which is used for the treatment of acute herpes zoster (shingles). also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in hiv infected patients. Famciclovir is a very strong basic compound (based on its pKa). |
|---|
| Structure | CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate | ChEBI | | 9-[4-Acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine | ChEBI | | Acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester | ChEBI | | BRL-42810 | ChEBI | | Famciclovirum | ChEBI | | Famvir | ChEBI | | FCV | ChEBI | | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetic acid | Generator | | Acetate 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester | Generator | | 9-(4-Acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine | HMDB |
|
|---|
| Chemical Formula | C14H19N5O4 |
|---|
| Average Molecular Weight | 321.3318 |
|---|
| Monoisotopic Molecular Weight | 321.143704121 |
|---|
| IUPAC Name | 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate |
|---|
| Traditional Name | famciclovir |
|---|
| CAS Registry Number | 104227-87-4 |
|---|
| SMILES | CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O |
|---|
| InChI Identifier | InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18) |
|---|
| InChI Key | GGXKWVWZWMLJEH-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as purines and purine derivatives. These are aromatic heterocyclic compounds containing a purine moiety, which is formed a pyrimidine-ring ring fused to an imidazole ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Imidazopyrimidines |
|---|
| Sub Class | Purines and purine derivatives |
|---|
| Direct Parent | Purines and purine derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Purine
- Aminopyrimidine
- Pyrimidine
- Dicarboxylic acid or derivatives
- N-substituted imidazole
- Azole
- Heteroaromatic compound
- Imidazole
- Amino acid or derivatives
- Carboxylic acid ester
- Carboxylic acid derivative
- Azacycle
- Amine
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 102 - 104 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 1.32 g/L | Not Available | | LogP | 0.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.79 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.2613 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.1 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 33.1 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1575.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 194.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 98.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 140.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 52.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 278.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 329.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 157.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 731.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 255.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1142.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 215.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 249.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 363.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 208.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 172.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Famciclovir,1TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C)N=C21)COC(C)=O | 2706.3 | Semi standard non polar | 33892256 | | Famciclovir,1TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C)N=C21)COC(C)=O | 2697.2 | Standard non polar | 33892256 | | Famciclovir,1TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C)N=C21)COC(C)=O | 4556.9 | Standard polar | 33892256 | | Famciclovir,2TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C)[Si](C)(C)C)N=C21)COC(C)=O | 2696.7 | Semi standard non polar | 33892256 | | Famciclovir,2TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C)[Si](C)(C)C)N=C21)COC(C)=O | 2783.8 | Standard non polar | 33892256 | | Famciclovir,2TMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C)[Si](C)(C)C)N=C21)COC(C)=O | 4020.5 | Standard polar | 33892256 | | Famciclovir,1TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 2850.5 | Semi standard non polar | 33892256 | | Famciclovir,1TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 2922.4 | Standard non polar | 33892256 | | Famciclovir,1TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 4426.2 | Standard polar | 33892256 | | Famciclovir,2TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 3092.0 | Semi standard non polar | 33892256 | | Famciclovir,2TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 3245.2 | Standard non polar | 33892256 | | Famciclovir,2TBDMS,isomer #1 | CC(=O)OCC(CCN1C=NC2=CN=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C21)COC(C)=O | 3978.4 | Standard polar | 33892256 |
|
|---|